New ADHD drug for young people
A new drug has been approved for the treatment of attention deficit/hyperactivity disorder in children and adolescents.
Lisdexamfetamine dimesylate (Elvanse) is a single-daily dose long-acting prodrug stimulant.
It has received marketing authorisation from the Medicines and Healthcare products Regulatory Agency for the treatment of ADHD in children aged six years and over when response to previous methylphenidate treatment is considered clinically inadequate.
Online training units, written and reviewed by experts. Earn two hours' CPD and a personalised certificate for your portfolio.
Subscribers get FREE unlimited access to all our online learning units and non-subscribers can access each learning unit for £10 + VAT.